Patents by Inventor Zhengyu Liu

Zhengyu Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PPAR ACTIVATORS
    Publication number: 20070191429
    Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
    Type: Application
    Filed: March 30, 2007
    Publication date: August 16, 2007
    Applicant: PFIZER INC.
    Inventors: Scott Bagley, Thomas Brandt, Robert Dugger, William Hada, Cheryl Hayward, Zhengyu Liu
  • Piperidine compounds useful as PPAR activators
    Patent number: 7199243
    Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: April 3, 2007
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Scott W. Bagley, Thomas A. Brandt, Robert W. Dugger, William A. Hada, Cheryl M. Hayward, Zhengyu Liu
  • Bicyclic derivatives for the treatment of abnormal cell growth
    Publication number: 20040254204
    Abstract: The invention relates to compounds of the formula 1 1
    Type: Application
    Filed: December 16, 2003
    Publication date: December 16, 2004
    Applicant: Pfizer Inc
    Inventors: John C. Kath, Zhengyu Liu, Maria S. Brown, Steven M. Winter, Susan J. Truesdell, Ruby A. Szewc
  • PPAR activators
    Publication number: 20040157885
    Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
    Type: Application
    Filed: November 24, 2003
    Publication date: August 12, 2004
    Applicant: Pfizer Inc
    Inventors: Scott W. Bagley, Thomas A. Brandt, Robert W. Dugger, William A. Hada, Cheryl M. Hayward, Zhengyu Liu
  • Substituted bicyclic derivatives useful as anticancer agents
    Patent number: 6541481
    Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R1, R3 and R4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: April 1, 2003
    Assignee: Pfizer Inc
    Inventors: John Charles Kath, Norma Jacqueline Tom, Zhengyu Liu, Eric David Cox, Joel Morris, Samit Kumar Bhattacharya
  • Substituted bicyclic derivatives useful as anticancer agents
    Publication number: 20010034351
    Abstract: The invention relates to compounds of the formula 1 1
    Type: Application
    Filed: April 12, 2001
    Publication date: October 25, 2001
    Inventors: John Charles Kath, Norma Jacqueline Tom, Zhengyu Liu, Eric David Cox, Joel Morris, Samit Kumar Bhattacharya
  • Substituted bicyclic derivatives useful as anticancer agents
    Patent number: 6284764
    Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R1, R3 and R4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: September 4, 2001
    Assignee: Pfizer Inc.
    Inventors: John Charles Kath, Norma Jacqueline Tom, Zhengyu Liu, Eric David Cox, Joel Morris, Samit Kumar Bhattacharya
  • Compounds and methods for increasing endogenous levels of corticotropin-releasing factor
    Patent number: 6133276
    Abstract: Ligand inhibitors for increasing levels of free corticotropin-releasing factor (CRF) in the brain are disclosed. Such ligand inhibitors cause release of CRF from the CRF/CRF-bind protein complex. Administration of the ligand inhibitors provide improvement in learning and memory, result in decreased food intake and/or provide treatment for diseases associated with low levels of CRF in the brain, notably Alzheimer's disease.
    Type: Grant
    Filed: December 29, 1998
    Date of Patent: October 17, 2000
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Jeffrey P. Whitten, James R. McCarthy, Zhengyu Liu, Charles Q. Huang, Philip E. Erickson, Dominic P. Behan
  • Compounds and methods for increasing endogenous levels of corticotropin-releasing factor
    Patent number: 5959109
    Abstract: Ligand inhibitors for increasing levels of free corticotropin-releasing factor (CRF) in the brain. Such ligand inhibitors cause release of CRF from the CRF/CRF-binding protein complex. Administration of the ligand inhibitors provide improvement in learning and memory, result in decreased food intake and/or provide treatment for diseases associated with low levels of CRF in the brain, notably Alzheimer's disease.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: September 28, 1999
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Jeffrey P. Whitten, James R. McCarthy, Zhengyu Liu, Charles Q. Huang, Philip E. Erickson, Dominic P. Behan